Lipo-C

Methionine / inositol / choline and B-vitamin multi-component research formulation

Component-resolved identity, chromatographic purity and quantitative assay; no single blend-wide purity value applies · target, verify batch COACAS Confirm per batch COARUO

Research statusComponent-level literature is available; no standardized Lipo-C composition or qualifying clinical efficacy study of the complete blend was identified

Supplied formMulti-component small-molecule and vitamin formulation (not a peptide)

Lead time14–21 days

Lipo-C — Form- and lot-specific research material; confirm physical form, colour, clarity and complete composition on the released-lot COA and label

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Defensible research value includes component-resolved analytical method development, formulation comparison, stability and container studies, and controlled investigation of component biology
Choline, methionine, inositol or vitamin studies may support a mechanistic hypothesis for a defined experiment, but they do not demonstrate weight loss, “detox”, energy enhancement, liver treatment or synergistic efficacy for a variable Lipo-C blend.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: Confirm per batch COA
Formula: Not applicable — mixture or multi-component material
Molecular weight: Component-specific; no single molecular weight
Appearance: Form- and lot-specific research material; confirm physical form, colour, clarity and complete composition on the released-lot COA and label
Purity: Component-resolved identity, chromatographic purity and quantitative assay; no single blend-wide purity value applies · target, verify batch COA
Storage: Follow the released-lot label, COA and formulation-specific stability data. Do not transfer room-temperature, refrigeration, after-opening or in-use instructions from a compounding-pharmacy product to a different research formulation. Quarantine temperature excursions or lots without traceable storage history.
MOQ: On request
Lead time: 14–21 days

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Lipo-C

Lipo-C and MIC are trade or formulation-family names rather than a single standardized chemical entity. Products sold under these names can contain different forms and concentrations of methionine, inositol, choline, vitamin B12 and optional additional ingredients. Evidence about an individual nutrient cannot establish the identity, stability, safety or efficacy of the complete blend. FDA explains that compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing; this catalogue item is a separate RUO research material and must not be represented as a compounded prescription or approved drug.

Appropriate laboratory contexts include identity and assay method development, declared-versus-measured composition, stereochemical or vitamin-form confirmation, impurity and undeclared-substance screening, formulation and container compatibility, stability, and controlled component-biology studies
No approved clinical indication applies to the blend.

Mechanism context

The question the literature is testing

Component biology is distinct: choline contributes to phosphatidylcholine synthesis and one-carbon metabolism; methionine participates in S-adenosylmethionine-dependent methyl transfer; inositol derivatives act in cell-signalling pathways; and the biochemical role of a B vitamin depends on its exact form. Combining these materials does not create a verified single-receptor mechanism or prove additive or synergistic efficacy. Every mechanistic interpretation must stay attached to the authenticated composition, matrix, concentration and model.

Evidence map

Research routes and exposure context

Evidence tierHuman clinical research

Research areaOther research materials

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not for human or veterinary administration
Variable or undisclosed composition, incorrect stereochemical or vitamin form, concentration error, degradation, particulates, contamination and unvalidated microbiological quality are material risks
A licensed-pharmacy statement or generic COA does not substitute for released-lot evidence
NIH nutrient upper limits and deficiency-treatment information apply to defined human intake contexts and must not be converted into instructions for this RUO blend.

Interactions reported in the literature

No human drug-combination or compatibility guidance applies
Laboratory mixture studies should use authenticated components, single-component controls, matrix controls and component-resolved analytics
GLP-1 medicines, stimulants or other prescription actives must not be assumed present, compatible or absent without testing.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Lipo-C factory batch COAs

Lipo-C 10 mL Factory batch COA protected preview

Lipo-C10 mL · WHJLP-LIPO10-260521-C

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require manufacturer and supply-chain traceability, exact quantitative formula, component form and CAS identity, orthogonal identity testing, component-resolved assay and impurities, water where relevant, solvent and excipient disclosure, pH and osmolality where relevant, particulates, fill amount, container integrity and lot-specific stability
Microbial limits, endotoxin and sterility require separate validated evidence when applicable
Reject a single “blend purity” value without component-level results.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

MIC-10ML10 ml10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-lot label, COA and formulation-specific stability data. Do not transfer room-temperature, refrigeration, after-opening or in-use instructions from a compounding-pharmacy product to a different research formulation. Quarantine temperature excursions or lots without traceable storage history.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Authoritative boundaries include FDA, “Compounding and the FDA: Questions and Answers,” which states that compounded drugs are not FDA approved or pre-reviewed for safety, effectiveness or quality; the NIH Office of Dietary Supplements Choline Fact Sheet for defined nutrient biology and intake limits; and peer-reviewed component-level literature already cited in this record. No qualifying randomized controlled trial or systematic review of a standardized complete Lipo-C/MIC formulation was identified.

01
Choline: an essential nutrient for public health
Nutrition Reviews · 2009 · peer-reviewed review article
Open source
02
Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline — Choline chapter
National Academies Press (US) / NCBI Bookshelf · 1998 · regulatory/landmark scientific consensus report
Open source
03
Choline, Its Potential Role in Nonalcoholic Fatty Liver Disease, and the Case for Human and Bacterial Genes
Advances in Nutrition · 2016 · peer-reviewed review article
Open source
04
Lipotropic Injections: Benefits, Side Effects, Dosage, and Cost
Healthline · 2024 · reputable consumer health journalism (medically reviewed)
Open source
05
Vitamin B-12 injections: An effective weight-loss aid?
Mayo Clinic · 2024 · authoritative institutional health guidance (medical center patient education page)
Open source
06
Safety Concerns Related to Fraudulent Compounding Practices Associated with Weight Loss Drugs
FBI Internet Crime Complaint Center (IC3) · 2025 · federal law-enforcement public service announcement / regulatory warning
Open source
07
Compounding and the FDA: Questions and Answers
U.S. Food and Drug Administration (FDA.gov) · 2024 · regulatory guidance/consumer information page
Open source

Product FAQ

Questions buyers ask about Lipo-C

Why must the methionine and B-vitamin forms be stated explicitly?+

L-methionine and DL-methionine differ stereochemically, while vitamin B12 may be supplied as cyanocobalamin, methylcobalamin, hydroxocobalamin or adenosylcobalamin. These forms are not universally interchangeable and have different identity records and analytical behaviour. The quotation, label and COA should name the exact form rather than using only “methionine” or “B12”.

How should purity and content be interpreted for this blend?+

A single HPLC area-percent result cannot establish the composition or mass balance of a multi-component formulation. Review identity and purity component by component, then review a quantitative assay for each declared component on a stated basis. Water, counterions, excipients and unlisted ingredients can affect mass balance without appearing as the principal chromatographic peak, so “99% pure blend” is not a decision-ready specification.

Lipo-C

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Lipo-C

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Lipo-C factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Choline: an essential nutrient for public health

Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline — Choline chapter

Choline, Its Potential Role in Nonalcoholic Fatty Liver Disease, and the Case for Human and Bacterial Genes

Lipotropic Injections: Benefits, Side Effects, Dosage, and Cost

Vitamin B-12 injections: An effective weight-loss aid?

Safety Concerns Related to Fraudulent Compounding Practices Associated with Weight Loss Drugs

Compounding and the FDA: Questions and Answers

Questions buyers ask about Lipo-C

Compare adjacent molecules and documentation needs.

L-Carnitine

Vitamin B12

Lemon Bottle

Adipotide (FTPP)